SIGA TECHNOLOGIES INC.

SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics

15 Jul 2022 07:30:00 By Nasdaq GlobeNewswire

SIGA Announces Approximately $28 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)

12 Jul 2022 16:15:00 By Nasdaq GlobeNewswire

SIGA Technologies Receives Approval from UK for Tecovirimat

08 Jul 2022 07:30:00 By Nasdaq GlobeNewswire

SIGA Announces $13 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)

23 Jun 2022 08:00:01 By Nasdaq GlobeNewswire

SIGA to Participate in Alliance Global Partners’ Monkeypox Panel on Thursday, June 23rd 2022

22 Jun 2022 10:13:44 By Nasdaq GlobeNewswire

SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)

19 May 2022 07:30:00 By Nasdaq GlobeNewswire

New Contract Awarded by U.S. Department of Defense for the Procurement of up to Approximately $7.5 Million of Oral TPOXX®

12 May 2022 16:05:01 By Nasdaq GlobeNewswire

SIGA Reports Financial Results for Three Months Ended March 31, 2022

05 May 2022 16:05:02 By Nasdaq GlobeNewswire

SIGA Declares Special Dividend of $0.45 Per Share

05 May 2022 07:30:01 By Nasdaq GlobeNewswire

SIGA Technologies to Host Business Update Call on May 5th, 2022 Following Release of First Quarter 2022 Financial Results

28 Apr 2022 16:05:02 By Nasdaq GlobeNewswire

SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2021

03 Mar 2022 16:05:01 By Nasdaq GlobeNewswire

SIGA Announces Start of TPOXX® Post-Exposure Prophylactic (“PEP”) Clinical Trials

02 Mar 2022 07:30:00 By Nasdaq GlobeNewswire

SIGA Technologies to Host Business Update Call on March 3rd, 2022 Following Release of Fourth Quarter and Full Year 2021 Financial Results

24 Feb 2022 10:27:12 By Nasdaq GlobeNewswire

SIGA Announces Preclinical Oncology Research Collaboration with Bioarchitech

25 Jan 2022 07:30:00 By Nasdaq GlobeNewswire

SIGA Technologies to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022

18 Jan 2022 07:30:00 By Nasdaq GlobeNewswire

SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat

10 Jan 2022 07:30:00 By Nasdaq GlobeNewswire

SIGA Announces Health Canada Regulatory Approval of Oral TPOXX®

01 Dec 2021 09:55:02 By Nasdaq GlobeNewswire

European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Recommends Approval of Tecovirimat

16 Nov 2021 08:30:00 By Nasdaq GlobeNewswire

SIGA Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2021

04 Nov 2021 16:05:01 By Nasdaq GlobeNewswire

SIGA Technologies to Host Business Update Call on November 4th, 2021, Following Release of Third Quarter 2021 Financial Results

28 Oct 2021 16:15:00 By Nasdaq GlobeNewswire